Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison

ConclusionEfgartigimod may provide a faster and greater improvement over 26 weeks in quality of life than ravulizumab in adults with AChR-Ab+  gMG. Efgartigimod showed faster improvements in MG-ADL and QMG than ravulizumab.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research